Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 2/20 | 0.48 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.48 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.41 |
| ▸ | NQO1 | P15559 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 3/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3819558 | 0.84 | CYP11B1 (0.51) | CYP11B1CYP11B2CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL21348220 | 0.84 | CHRNB2 (0.41) | CHRNB2CHRNA4GRM5 | |
| SCHEMBL25636829 | 0.82 | CYP2D6 (0.44) | — | |
| SCHEMBL24935432 | 0.81 | GRM5 (0.40) | CHRNB2CHRNA4GRM5 | |
| SCHEMBL29632650 | 0.81 | GRM5 (0.40) | CHRNB2CHRNA4GRM5 | |
| SCHEMBL14300807 | 0.79 | CHRNB2 (0.46) | CHRNB2CHRNA4GRM5 | |
| SCHEMBL21348286 | 0.77 | TDP1 (0.44) | CHRNB2CHRNA4GRM5 | |
| SCHEMBL24680182 | 0.77 | GRM5 (0.37) | CHRNB2CHRNA4GRM5 | |
| SCHEMBL10781062 | 0.77 | CYP11B1 (0.58) | CYP11B1CYP11B2CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL10061804 | 0.77 | CHRNB2 (0.47) | CYP11B1CYP11B2CHRNB2CHRNA4CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240140937-A1 | Diacylglycerol Acyl Transferase 2 Inhibitors | PFIZER INC. (US) | 2024-05-02 | — | — | US | disclosed |
| US-11866425-B2 | Diacylglycerol acyl transferase 2 inhibitors | PFIZER INC. (US) | 2024-01-09 | — | — | US | disclosed |
| US-20230405002-A1 | COMBINATIONS OF DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS AND ACETYL-COA CARBOXYLASE INHIBITOR | PFIZER INC. (US) | 2023-12-21 | — | — | US | disclosed |
| WO-2023067322-A1 | TRICYCLIC GPR65 MODULATORS | Pathios Therapeutics Limited (GB) | 2023-04-27 | — | — | WO | disclosed |
| US-11471458-B2 | Diacylglycerol acyl transferase 2 inhibitor | PFIZER INC. (US) | 2022-10-18 | — | — | US | disclosed |
| US-20210309646-A1 | DIACYLGLYCEROL ACYL TRANSFERASE 2 INHIBITORS | PFIZER INC. (US) | 2021-10-07 | — | — | US | disclosed |
| CN-109641875-B | Diacylglycerol acyltransferase 2 inhibitors | 辉瑞公司 | 2021-08-31 | — | — | CN | disclosed |
| US-11034678-B2 | Diacylglycerol acyl transferase 2 inhibitors | PFIZER INC. (US) | 2021-06-15 | — | — | US | disclosed |
| EP-3500564-B1 | DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS | PFIZER (US) | 2020-10-07 | — | — | EP | disclosed |
| US-20200181127-A1 | DIACYLGLYCEROL ACYL TRANSFERASE 2 INHIBITORS | PFIZER INC. (US) | 2020-06-11 | — | — | US | disclosed |
| EP-3500564-A1 | DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS | Pfizer Inc (US) | 2019-06-26 | — | — | EP | disclosed |
| US-20180258081-A1 | DIACYLGLYCEROL ACYL TRANSFERASE 2 INHIBITORS | PFIZER INC. (US) | 2018-09-13 | — | — | US | disclosed |
| US-10071992-B2 | Diacylglycerol acyl transferase 2 inhibitors | PFIZER INC. (US) | 2018-09-11 | — | — | US | disclosed |
| US-20180051012-A1 | DIACYLGLYCEROL ACYL TRANSFERASE 2 INHIBITORS | PFIZER INC. (US) | 2018-02-22 | — | — | US | disclosed |
| WO-2018033832-A1 | DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS | PFIZER INC. (US) | 2018-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200181127-A1 | DIACYLGLYCEROL ACYL TRANSFERASE 2 INHIBITORS | DGAT2, DGAT1, LCLAT1 | CYP11B1 1963/4885CYP11B2 1662/4885CHRNB2 2482/4885 |
| US-20180258081-A1 | DIACYLGLYCEROL ACYL TRANSFERASE 2 INHIBITORS | DGAT2, DGAT1, LCLAT1 | CYP11B1 1963/4885CYP11B2 1662/4885CHRNB2 2482/4885 |
| US-10071992-B2 | Diacylglycerol acyl transferase 2 inhibitors | DGAT2, DGAT1, LCLAT1 | CYP11B1 1963/4885CYP11B2 1662/4885CHRNB2 2482/4885 |
| US-20210309646-A1 | DIACYLGLYCEROL ACYL TRANSFERASE 2 INHIBITORS | DGAT2, DGAT1, LCLAT1 | CYP11B1 1963/4885CYP11B2 1662/4885CHRNB2 2482/4885 |
| US-11866425-B2 | Diacylglycerol acyl transferase 2 inhibitors | DGAT2, DGAT1, LCLAT1 | CYP11B1 1963/4885CYP11B2 1662/4885CHRNB2 2482/4885 |
| US-20230405002-A1 | COMBINATIONS OF DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS AND ACETYL-COA CARBOXYLASE INHIBITOR | ACAT2, ACACB, ACACA | CYP11B1 1537/4885CYP11B2 1419/4885CHRNB2 4106/4885 |
| US-20180051012-A1 | DIACYLGLYCEROL ACYL TRANSFERASE 2 INHIBITORS | DGAT2, DGAT1, LCLAT1 | CYP11B1 1963/4885CYP11B2 1662/4885CHRNB2 2482/4885 |
| US-11471458-B2 | Diacylglycerol acyl transferase 2 inhibitor | DGAT2, DGAT1, ACAT2 | CYP11B1 1982/4885CYP11B2 2119/4885CHRNB2 4315/4885 |
| US-11034678-B2 | Diacylglycerol acyl transferase 2 inhibitors | DGAT2, DGAT1, LCLAT1 | CYP11B1 1963/4885CYP11B2 1662/4885CHRNB2 2482/4885 |
| US-20240140937-A1 | Diacylglycerol Acyl Transferase 2 Inhibitors | DGAT2, DGAT1, LCLAT1 | CYP11B1 1963/4885CYP11B2 1662/4885CHRNB2 2482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.